Sorry, you need to enable JavaScript to visit this website.


Aimmune Therapeutics, Inc., was founded in direct response to a united call to action by leading stakeholders in food allergy.

In 2011, at an advocacy-sponsored retreat for food allergy treatment research, parents of children with severe peanut allergy, patient advocacy organizations, leading clinical and academic physicians, and members of the pharmaceutical industry concluded that there was a significant unmet need for a standard oral immunotherapy (OIT) approach and treatments.

This consensus-driven community ultimately led to the formation of the Allergen Research Corporation, the forerunner to Aimmune Therapeutics, to specifically address this need and fulfill a unified vision.



Three children look straight ahead